Gastrointestinal Cancer | Specialty

First-Line Therapy in Advanced HCC

April 24th 2018

When to Move to Systemic Therapy in HCC

April 24th 2018

HCC: Role of Radiotherapy and Measuring Response

April 24th 2018

When to Use Locoregional Therapies in HCC

April 24th 2018

HCC: Criteria for Resection and Adjuvant Therapy

April 24th 2018

Multidisciplinary Team Approach to Treating HCC

April 24th 2018

Methods for Staging HCC

April 24th 2018

Diagnostic Evaluation of HCC

April 24th 2018

Dr. Kopetz Discusses the Treatment of BRAF-Mutant CRC

April 21st 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with BRAF-mutant colorectal cancer.

Expert Shares Insight on Navigating Neuroendocrine Tumor Treatment

April 20th 2018

Paul R. Helft, MD, discusses the incidence of gastrointestinal neuroendocrine tumors and available and emerging treatment methods.

Therapeutic Options Continue to Grow for HCC

April 20th 2018

Tanios Bekaii-Saab, MD, sheds light on the recent advances in the treatment of patients with hepatocellular carcinoma.

Epacadostat Falls Short Again

April 17th 2018

Adding the IDO1 inhibitor epacadostat to the PD-L1 inhibitor durvalumab (Imfinzi) failed to induce any clinical responses in patients with pancreatic cancer.

Dr. Bekaii-Saab on Napabucasin in Patients With Pancreatic Cancer

April 12th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the potential of napabucasin, previously known as BBI-608, in patients with pancreatic cancer.

Dr. Bhoola on Enhanced Recovery After Surgery in Gynecologic Cancer

April 12th 2018

Snehal Bhoola, MD, assistant professor, Mercer University School of Medicine, associate professor, University of Arizona, Arizona Oncology, discusses enhanced recovery after surgery (ERAS) in gynecologic malignancies.

Role of Immunotherapies Emerging in Gastric/GEJ Cancers

April 11th 2018

Andrew Ko, MD, discusses how the approval of pembrolizumab has impacted patients with positive PD-L1 expression and how clinical trials that have reshaped the standard of care in patients with gastric and GEJ cancers.

HCC Trials Spur Treatment Landscape Forward

April 11th 2018

R. Kate Kelley, MD, discusses the incidence of and risk factors for HCC, and emphasizes the sequence of clinical trials that characterized the field in 2017.

Dr. Van Loon Discusses the Management of Rectal Cancer

April 10th 2018

Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the management of rectal cancer.

Dr. Shah on the Relationship Between H. Pylori and Immune Response in Gastric Cancer

April 10th 2018

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the relationship between helicobacter pylori (H. pylori) and immune response in gastric cancer.

Dr. Singh Discusses the Next Steps for Immunotherapy in GISTs

April 10th 2018

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses the next steps following a trial investigating single-agent and combination immunotherapy for patients with gastrointestinal stromal tumors (GIST).

Tempero Spotlights Frontline Treatment Options in Pancreatic Cancer

April 10th 2018

Margaret A. Tempero, MD, discusseds frontline treatment options in pancreatic cancer and emphasized the use and difficulties of conventional and incoming therapies across disease states.